S&P 500   3,232.86 (-3.14%)
DOW   28,055.45 (-3.23%)
QQQ   221.99 (-3.60%)
AAPL   299.71 (-4.26%)
MSFT   171.86 (-3.77%)
AMZN   2,003.11 (-4.43%)
CGC   20.45 (-6.54%)
NVDA   276.05 (-6.13%)
BABA   204.39 (-3.86%)
MU   54.75 (-3.95%)
GE   11.89 (-3.02%)
TSLA   839.72 (-6.80%)
AMD   49.19 (-7.68%)
T   38.21 (-0.88%)
ACB   1.56 (-6.59%)
F   7.63 (-3.30%)
BAC   32.76 (-4.66%)
GILD   72.23 (+3.63%)
S&P 500   3,232.86 (-3.14%)
DOW   28,055.45 (-3.23%)
QQQ   221.99 (-3.60%)
AAPL   299.71 (-4.26%)
MSFT   171.86 (-3.77%)
AMZN   2,003.11 (-4.43%)
CGC   20.45 (-6.54%)
NVDA   276.05 (-6.13%)
BABA   204.39 (-3.86%)
MU   54.75 (-3.95%)
GE   11.89 (-3.02%)
TSLA   839.72 (-6.80%)
AMD   49.19 (-7.68%)
T   38.21 (-0.88%)
ACB   1.56 (-6.59%)
F   7.63 (-3.30%)
BAC   32.76 (-4.66%)
GILD   72.23 (+3.63%)
S&P 500   3,232.86 (-3.14%)
DOW   28,055.45 (-3.23%)
QQQ   221.99 (-3.60%)
AAPL   299.71 (-4.26%)
MSFT   171.86 (-3.77%)
AMZN   2,003.11 (-4.43%)
CGC   20.45 (-6.54%)
NVDA   276.05 (-6.13%)
BABA   204.39 (-3.86%)
MU   54.75 (-3.95%)
GE   11.89 (-3.02%)
TSLA   839.72 (-6.80%)
AMD   49.19 (-7.68%)
T   38.21 (-0.88%)
ACB   1.56 (-6.59%)
F   7.63 (-3.30%)
BAC   32.76 (-4.66%)
GILD   72.23 (+3.63%)
S&P 500   3,232.86 (-3.14%)
DOW   28,055.45 (-3.23%)
QQQ   221.99 (-3.60%)
AAPL   299.71 (-4.26%)
MSFT   171.86 (-3.77%)
AMZN   2,003.11 (-4.43%)
CGC   20.45 (-6.54%)
NVDA   276.05 (-6.13%)
BABA   204.39 (-3.86%)
MU   54.75 (-3.95%)
GE   11.89 (-3.02%)
TSLA   839.72 (-6.80%)
AMD   49.19 (-7.68%)
T   38.21 (-0.88%)
ACB   1.56 (-6.59%)
F   7.63 (-3.30%)
BAC   32.76 (-4.66%)
GILD   72.23 (+3.63%)
Log in

NASDAQ:ARRY - Array Biopharma Stock Price, Forecast & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
$47.85
0.00 (0.00 %)
(As of 02/24/2020 12:28 PM ET)
Today's Range
$47.85
Now: $47.85
$47.85
50-Day Range
$47.85
MA: $47.85
$47.85
52-Week Range
$12.56
Now: $47.85
$47.98
VolumeN/A
Average Volume4.99 million shs
Market Capitalization$10.68 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.7
Array BioPharma Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer and other diseases in North America, Europe, and the Asia Pacific. It provides BRAFTOVITM (encorafenib) capsules in combination with MEKTOVI (binimetinib) tablets for the treatment of patients with unresectable or metastatic melanoma with a BRAF mutation. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:ARRY
CUSIP04269X10
Phone303-381-6600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$173.77 million
Book Value$1.04 per share

Profitability

Net Income$-147,340,000.00

Miscellaneous

Employees298
Market Cap$10.68 billion
Next Earnings DateN/A
OptionableOptionable

Receive ARRY News and Ratings via Email

Sign-up to receive the latest news and ratings for ARRY and its competitors with MarketBeat's FREE daily newsletter.


Array Biopharma (NASDAQ:ARRY) Frequently Asked Questions

What is Array Biopharma's stock symbol?

Array Biopharma trades on the NASDAQ under the ticker symbol "ARRY."

How were Array Biopharma's earnings last quarter?

Array Biopharma Inc (NASDAQ:ARRY) issued its earnings results on Tuesday, October, 30th. The biopharmaceutical company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.22) by $0.10. The biopharmaceutical company earned $56.91 million during the quarter, compared to analysts' expectations of $34.47 million. Array Biopharma had a negative return on equity of 48.51% and a negative net margin of 52.64%. Array Biopharma's revenue was up 91.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($0.22) earnings per share. View Array Biopharma's Earnings History.

What price target have analysts set for ARRY?

10 equities research analysts have issued 12 month price targets for Array Biopharma's stock. Their forecasts range from $25.00 to $48.00. On average, they expect Array Biopharma's stock price to reach $40.03 in the next year. This suggests that the stock has a possible downside of 16.3%. View Analyst Price Targets for Array Biopharma.

What is the consensus analysts' recommendation for Array Biopharma?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Array Biopharma in the last year. There are currently 9 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Array Biopharma.

Has Array Biopharma been receiving favorable news coverage?

News headlines about ARRY stock have been trending very negative this week, according to InfoTrie. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Array Biopharma earned a media sentiment score of -3.2 on InfoTrie's scale. They also gave news articles about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Array Biopharma.

Who are some of Array Biopharma's key competitors?

What other stocks do shareholders of Array Biopharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Array Biopharma investors own include Puma Biotechnology (PBYI), BioMarin Pharmaceutical (BMRN), Medivation (MDVN), Incyte (INCY), First Solar (FSLR), Dynavax Technologies (DVAX), United Continental (UAL), Exelixis (EXEL), Kite Pharma (KITE) and Omeros (OMER).

Who are Array Biopharma's key executives?

Array Biopharma's management team includes the folowing people:
  • Mr. Ron Squarer, CEO & Director (Age 52)
  • Mr. Jason Haddock, Chief Financial Officer (Age 49)
  • Mr. Andrew R. Robbins, Chief Operating Officer (Age 43)
  • Dr. Victor Sandor, Chief Medical Officer (Age 53)
  • Dr. Nicholas A. Saccomano, Chief Scientific Officer (Age 60)

Who are Array Biopharma's major shareholders?

Array Biopharma's stock is owned by many different of retail and institutional investors. Top institutional investors include Baxter Bros Inc. (0.02%) and Baxter Bros Inc. (0.02%). Company insiders that own Array Biopharma stock include Andrew R Robbins, Carrie Smith Cox, Curtis Gale Oltmans, Jason Haddock, Kyle Lefkoff, Lunsen Gil J Van, Nicholas A Saccomano, Ron Squarer and Victor Sandor. View Institutional Ownership Trends for Array Biopharma.

Which institutional investors are buying Array Biopharma stock?

ARRY stock was bought by a variety of institutional investors in the last quarter, including Baxter Bros Inc. and Baxter Bros Inc.. View Insider Buying and Selling for Array Biopharma.

What is Array Biopharma's stock price today?

One share of ARRY stock can currently be purchased for approximately $47.85.

How big of a company is Array Biopharma?

Array Biopharma has a market capitalization of $10.68 billion and generates $173.77 million in revenue each year. The biopharmaceutical company earns $-147,340,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Array Biopharma employs 298 workers across the globe.View Additional Information About Array Biopharma.

What is Array Biopharma's official website?

The official website for Array Biopharma is http://www.arraybiopharma.com/.

How can I contact Array Biopharma?

Array Biopharma's mailing address is 3200 Walnut Street, Boulder CO, 80301. The biopharmaceutical company can be reached via phone at 303-381-6600 or via email at [email protected]


MarketBeat Community Rating for Array Biopharma (NASDAQ ARRY)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  502 (Vote Outperform)
Underperform Votes:  326 (Vote Underperform)
Total Votes:  828
MarketBeat's community ratings are surveys of what our community members think about Array Biopharma and other stocks. Vote "Outperform" if you believe ARRY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARRY will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/24/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel